Cited by 535Alzheimer's disease research and treatmentsNeuroscience and Neuropharmacology ResearchNeuroinflammation and Neurodegeneration Mechanisms

The Role of NMDA Receptors in Alzheimer’s Disease

Open access
Liu, Jinping, Chang, Lirong, Song, Yizhi, Li, Hui, Wu, Yan·2019·Frontiers in Neuroscience

Abstract

In Alzheimer's disease (AD), early synaptic dysfunction is associated with the increased oligomeric amyloid-beta peptide, which causes NMDAR-dependent synaptic depression and spine elimination. Memantine, low-affinity NMDAR channel blocker, has been used in the treatment of moderate to severe AD. However, clear evidence is still deficient in demonstrating the underlying mechanisms and a relationship between NMDARs dysfunction and AD. This review focuses on not only changes in expression of different NMDAR subunits, but also some unconventional modes of NMDAR action.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.3389/fnins.2019.00043

Cites

339 of 339 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • N-methyl-d-aspartate receptor (NMDAR) activation and related excitotoxic events that lead to synaptic dysfunction are associated with AD pathology.

    “N-methyl-d-aspartate receptor (NMDAR) activation and related excitotoxic events that lead to synaptic dysfunction has also been associated with AD pathology (Liu et al. 2019).”

    From Alzheimer’s disease: Targeting the glutamatergic system (2020) · cites this paper as Liu et al. 2019

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Authors
Liu, J., Chang, L., Song, Y., Li, H., & Wu, Y.
Affiliations
  • Tsinghua University (CN)
  • Capital Medical University (CN)
Corresponding author
Wu, Yan
Venue
Frontiers in Neuroscience
Published
2019-02-08
Volume
13
Pages
43-43
ISSN
1662-453X (ISSN-L)
OpenAlex
W2911747652
Cited by
535
References
339
Citations by year
2026: 51 · 2025: 80 · 2024: 82 · 2023: 103 · 2022: 92 · 2021: 71 · 2020: 47 · 2019: 9
FWCI
6.45
Type
journal article
Language
en
Open access
Locations
  • Frontiers in Neuroscience (publishedVersion, cc-by)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Topics
  • Health Sciences › Medicine › Physiology › Alzheimer's disease research and treatments
  • Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neuroscience and Neuropharmacology Research
  • Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
Keywords
NMDA receptor, Alzheimer's disease, amyloid-beta oligomers, synaptic dysfunction, synaptic depression, memantine, NMDA receptor subunits

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review